We use data from Alzheimer’s Disease and Neuroimaging Initiative (ADNI) to assess whether the addition of MRI volumetric measures in key regions of the brain and CSF-based biomarkers (Aß and P-tau) improve cognitive status classification, that is classification as having dementia, cognitive impairment without dementia or being cognitively normal, relative to cognitive performance examinations normally included in population surveys. The gene discussed is MAPT; the disease is Cognitive impairment.